Biopharmx Corp BPMX shares spiked higher Tuesday morning after the company announced its Phase 2b trial of BPX-04 for Populopustular Rosacea has met both primary and secondary endpoints and was well tolerated.
This news pushed BioPharmX from 88 cents to $1.27 per share, but the stock traded around 84 cents at time of publication.
Related Links:
Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues
Acer Therapeutics Shares Plunge On FDA Complete Response Letter
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
